{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:24:14Z","timestamp":1790763854220,"version":"4.1.0"},"reference-count":230,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Since the discovery of the LDL receptor in 1973 by Brown and Goldstein as a causative protein in hypercholesterolemia, tremendous amounts of effort have gone into finding ways to manage high LDL cholesterol in familial hypercholesterolemic (HoFH and HeFH) individuals with loss-of-function mutations in the LDL receptor (LDLR) gene. Statins proved to be the first blockbuster drug, helping both HoFH and HeFH individuals by inhibiting the cholesterol synthesis pathway rate-limiting enzyme HMG-CoA reductase and inducing the LDL receptor. However, statins could not achieve the therapeutic goal of LDL. Other therapies targeting LDLR include PCSK9, which lowers LDLR by promoting LDLR degradation. Inducible degrader of LDLR (IDOL) also controls the LDLR protein, but an IDOL-based therapy is yet to be developed. Among the LDLR-independent pathways, such as angiopoietin-like 3 (ANGPTL3), apolipoprotein (apo) B, apoC-III and CETP, only ANGPTL3 offers the advantage of treating both HoFH and HeFH patients and showing relatively better preclinical and clinical efficacy in animal models and hypercholesterolemic individuals, respectively. While loss-of-LDLR-function mutations have been known for decades, gain-of-LDLR-function mutations have recently been identified in some individuals. The new information on gain of LDLR function, together with CRISPR-Cas9 genome\/base editing technology to target LDLR and ANGPTL3, offers promise to HoFH and HeFH individuals who are at a higher risk of developing atherosclerotic cardiovascular disease (ASCVD).<\/jats:p>","DOI":"10.3390\/cells12121648","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T08:56:01Z","timestamp":1686905761000},"page":"1648","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD"],"prefix":"10.3390","volume":"12","author":[{"given":"Rai Ajit K.","family":"Srivastava","sequence":"first","affiliation":[{"name":"Integrated Pharma Solutions LLC, Boston, MA 02101-02117, USA"},{"name":"College of Professional Studies, Northeastern University, Boston, MA 02101-02117, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0025-7125(16)31424-9","article-title":"The LDL receptor defect in familial hypercholesterolemia: Implications for pathogenesis and therapy","volume":"66","author":"Goldstein","year":"1982","journal-title":"Med. Clin. N. Am."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2217\/pgs.15.113","article-title":"Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment","volume":"16","author":"Santos","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11886-017-0848-8","article-title":"Genetic Architecture of Familial Hypercholesterolaemia","volume":"19","author":"Sharifi","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5551\/jat.RV17050","article-title":"Homozygous Familial Hypercholesterolemia","volume":"28","author":"Nohara","year":"2021","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2005.08.015","article-title":"Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia","volume":"186","author":"Pisciotta","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2021.08.024","article-title":"Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry","volume":"333","author":"Desperak","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.numecd.2021.05.024","article-title":"Discovery of analogues of non-\u03b2 oxidizable long-chain dicarboxylic fatty acids as dual inhibitors of fatty acids and cholesterol synthesis: Efficacy of lead compound in hyperlipidemic hamsters reveals novel mechanism","volume":"31","author":"Srivastava","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0022-2275(20)32125-8","article-title":"Molecular bases of low production rates of apolipoprotein B-100 and truncated apoB-82 in a mutant HepG2 cell line generated by targeted modification of the apolipoprotein B gene","volume":"40","author":"Srivastava","year":"1999","journal-title":"J. Lipid Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1161\/01.ATV.19.4.1105","article-title":"Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression","volume":"19","author":"Plump","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1194\/jlr.M032615","article-title":"Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib","volume":"54","author":"Davidson","year":"2013","journal-title":"J. Lipid Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1172\/JCI116663","article-title":"Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery","volume":"92","author":"Ishibashi","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Benito-Vicente, A., Uribe, K.B., Jebari, S., Galicia-Garcia, U., Ostolaza, H., and Martin, C. (2018). Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113426"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MOL.0000000000000760","article-title":"Role of VLDL receptor in atherogenesis","volume":"32","author":"Takahashi","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1172\/JCI29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_18","first-page":"103","article-title":"Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression","volume":"27","author":"Dong","year":"2011","journal-title":"Int. J. Mol. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2174\/0929867324666170609081612","article-title":"APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia","volume":"25","author":"Schmitz","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jacl.2022.06.011","article-title":"Volanesorsen, an antisense oligonucleotide to apolipoprotein C-III, increases lipoprotein lipase activity and lowers triglycerides in partial lipodystrophy","volume":"16","author":"Lightbourne","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2011.02.010","article-title":"Effects of ezetimibe on atherosclerosis in preclinical models","volume":"215","author":"Davis","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacl.2013.06.011","article-title":"Lowering LDL cholesterol, but not raising LDL receptor activity, by ezetimibe","volume":"7","author":"Hayashi","year":"2013","journal-title":"J. Clin. Lipidol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)","volume":"102","author":"Lisnock","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00129784-200404060-00009","article-title":"Ezetimibe\/Simvastatin: A review of its use in the management of hypercholesterolemia","volume":"4","author":"Murdoch","year":"2004","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.atherosclerosis.2005.06.039","article-title":"The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy","volume":"186","author":"Yamamoto","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clinthera.2016.11.014","article-title":"Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk","volume":"39","author":"Yang","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1021\/acs.molpharmaceut.2c00007","article-title":"Bile Acid Sequestrants for Hypercholesterolemia Treatment Using Sustainable Biopolymers: Recent Advances and Future Perspectives","volume":"19","author":"Islam","year":"2022","journal-title":"Mol. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.1965.03080170017004","article-title":"Cholestyramine Resin Therapy for Hypercholesteremia: Clinical and Metabolic Studies","volume":"192","author":"Hashim","year":"1965","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000174547","article-title":"Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels","volume":"76","author":"LaRosa","year":"1989","journal-title":"Cardiology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1472-8206.2007.00530.x","article-title":"Nicotinic acid in the treatment of hyperlipidaemia","volume":"21","author":"Drexel","year":"2007","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"20b","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1345\/aph.1C161","article-title":"Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia","volume":"37","author":"Yim","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.2165\/0003495-200868160-00008","article-title":"Niacin extended-release\/simvastatin","volume":"68","author":"Sanford","year":"2008","journal-title":"Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11883-020-00858-4","article-title":"Lomitapide\u2014A Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia","volume":"22","author":"Stefanutti","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/14656566.2018.1550071","article-title":"Mipomersen and its use in familial hypercholesterolemia","volume":"20","author":"Parham","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/VHRM.S191965","article-title":"Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes","volume":"18","author":"Alur","year":"2022","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11883-014-0465-6","article-title":"Lipoprotein apheresis in the management of familial hypercholesterolaemia: Historical perspective and recent advances","volume":"17","author":"Stefanutti","year":"2015","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1210\/clinem\/dgab876","article-title":"New Therapies for Primary Hyperlipidemia","volume":"107","author":"Corral","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0149-2918(97)80102-6","article-title":"Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: A meta-analysis of clinical trials","volume":"19","author":"Kong","year":"1997","journal-title":"Clin. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","article-title":"Lomitapide and mipomersen: Two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia","volume":"129","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CRD.0b013e31823424be","article-title":"Mipomersen: A safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia","volume":"20","author":"Ricotta","year":"2012","journal-title":"Cardiol. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/TCRM.S150476","article-title":"Positive correlation of the serum angiopoietin-like protein 3 levels with the aortic augmentation index in patients with coronary artery disease","volume":"14","author":"Fu","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FJC.0000000000001073","article-title":"Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis","volume":"78","author":"Jin","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/17512433.2022.2047934","article-title":"Evinacumab for the treatment of homozygous familial hypercholesterolemia","volume":"15","author":"Gao","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11883-022-01071-1","article-title":"ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis","volume":"24","author":"Mohamed","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"ytad029","DOI":"10.1093\/ehjcr\/ytad029","article-title":"Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: A case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms","volume":"7","author":"Khoury","year":"2023","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","article-title":"ANGPTL3 Deficiency and Protection Against Coronary Artery Disease","volume":"69","author":"Stitziel","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/MOL.0000000000000789","article-title":"ANGPTL3 as therapeutic target","volume":"32","author":"Kersten","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosissup.2017.05.003","article-title":"The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia","volume":"30","year":"2017","journal-title":"Atheroscler. Suppl."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e13841","DOI":"10.1111\/eci.13841","article-title":"Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials","volume":"52","author":"Calcaterra","year":"2022","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11883-021-00914-7","article-title":"ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets","volume":"23","author":"Akoumianakis","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_63","first-page":"377","article-title":"Bempedoic Acid (Nexletol) for the Treatment of Hyperlipidemia and Familial Hypercholesterolemia","volume":"103","author":"Lawrence","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"99s","DOI":"10.1016\/j.amjmed.2003.09.016","article-title":"Endothelial function, inflammation, and prognosis in cardiovascular disease","volume":"115","author":"Gonzalez","year":"2003","journal-title":"Am. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2337\/diabetes.53.3.701","article-title":"Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment","volume":"53","author":"Ceriello","year":"2004","journal-title":"Diabetes"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1615\/CritRevImmunol.2018026483","article-title":"How Oxidized Low-Density Lipoprotein Activates Inflammatory Responses","volume":"38","author":"Rhoads","year":"2018","journal-title":"Crit. Rev. Immunol."},{"key":"ref_68","first-page":"89","article-title":"Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease","volume":"3","author":"Gao","year":"2017","journal-title":"Chronic Dis. Transl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11010-017-3165-z","article-title":"Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease","volume":"440","author":"Srivastava","year":"2018","journal-title":"Mol. Cell. Biochem."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2018.03.128","article-title":"LDL particle size and composition and incident cardiovascular disease in a South-European population: The Hortega-Liposcale Follow-up Study","volume":"264","author":"Pichler","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Li, C., Chen, Q., Zhang, M., Liu, Y., Chu, Y., Meng, F., Wang, J., Tang, J., Luo, J., and Niu, X. (2021). The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg\/dL. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-021-01861-6"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Gareri, C., Polimeni, A., Giordano, S., Tamm\u00e8, L., Curcio, A., and Indolfi, C. (2022). Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias. J. Clin. Med., 11.","DOI":"10.3390\/jcm11133884"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia","volume":"74","author":"Koren","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurjpc\/zwaa097","article-title":"Safety and efficacy of alirocumab in a real-life setting: The ODYSSEY APPRISE study","volume":"28","author":"Gaudet","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11883-020-00886-0","article-title":"Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia","volume":"22","author":"Pokrovsky","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1016\/S0021-9258(19)42341-7","article-title":"Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia","volume":"249","author":"Goldstein","year":"1974","journal-title":"J. Biol. Chem."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJM198108273050902","article-title":"Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia","volume":"305","author":"Mabuchi","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0026-0495(85)90015-0","article-title":"The association of LDL receptor activity, LDL cholesterol level, and clinical course in homozygous familial hypercholesterolemia","volume":"34","author":"Sprecher","year":"1985","journal-title":"Metabolism"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/0026-0495(91)90132-G","article-title":"Pravastatin in heterozygous familial hypercholesterolemia: Low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS","volume":"40","author":"Gaddi","year":"1991","journal-title":"Metabolism"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/eci.12304","article-title":"Most appropriate animal models to study the efficacy of statins: A systematic review","volume":"44","author":"Pecoraro","year":"2014","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJM199007263230403","article-title":"Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol","volume":"323","author":"Rudling","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Barale, C., Melchionda, E., Morotti, A., and Russo, I. (2021). PCSK9 Biology and Its Role in Atherothrombosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115880"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1194\/jlr.M028563","article-title":"Molecular characterization of proprotein convertase subtilisin\/kexin type 9-mediated degradation of the LDLR","volume":"53","author":"Wang","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.ATV.0000255311.26383.2f","article-title":"A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol","volume":"27","author":"Fasano","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"78813","DOI":"10.18632\/oncotarget.12385","article-title":"miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3","volume":"7","author":"Shan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.2147\/OTT.S167771","article-title":"miR-185 suppresses progression of Ewing\u2019s sarcoma via inhibiting the PI3K\/AKT and Wnt\/\u03b2-catenin pathways","volume":"11","author":"Zhang","year":"2018","journal-title":"Onco Targets Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5507\/bp.2019.030","article-title":"The effect of quercetin on microRNA expression: A critical review","volume":"163","author":"Dostal","year":"2019","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm.3949","article-title":"MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels","volume":"21","author":"Goedeke","year":"2015","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.atherosclerosis.2015.10.026","article-title":"microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator","volume":"243","author":"Jiang","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1517\/13543784.2011.547471","article-title":"Mipomersen, an antisense apolipoprotein B synthesis inhibitor","volume":"20","author":"Bell","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"23","DOI":"10.12997\/jla.2023.12.1.23","article-title":"New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3","volume":"12","author":"Kim","year":"2023","journal-title":"J. Lipid Atheroscler."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0022-2275(20)32397-X","article-title":"Intracellular mechanisms regulating apoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes","volume":"41","author":"Taghibiglou","year":"2000","journal-title":"J. Lipid Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1007030531478","article-title":"Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB","volume":"202","author":"Srivastava","year":"1999","journal-title":"Mol. Cell. Biochem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1007111830472","article-title":"High density lipoprotein, apolipoprotein A-I, and coronary artery disease","volume":"209","author":"Srivastava","year":"2000","journal-title":"Mol. Cell. Biochem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0026-0495(96)90251-6","article-title":"A new apolipoprotein B truncation (apo B-43.7) in familial hypobetalipoproteinemia: Genetic and metabolic studies","volume":"45","author":"Srivastava","year":"1996","journal-title":"Metabolism"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1194\/jlr.M200342-JLR200","article-title":"Fatty liver in familial hypobetalipoproteinemia: Triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis","volume":"44","author":"Schonfeld","year":"2003","journal-title":"J. Lipid Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.bbrc.2010.06.130","article-title":"The production of 85 kDa N-terminal fragment of apolipoprotein B in mutant HepG2 cells generated by targeted modification of apoB gene occurs by ALLN-inhibitable protease cleavage during translocation","volume":"398","author":"Srivastava","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2009.01.037","article-title":"Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia","volume":"206","author":"Noto","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00592-016-0931-4","article-title":"Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature","volume":"54","author":"Noto","year":"2017","journal-title":"Acta Diabetol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2018.03.019","article-title":"New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?","volume":"272","author":"Olkkonen","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1538\/expanim.55.27","article-title":"Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity","volume":"55","author":"Fujimoto","year":"2006","journal-title":"Exp. Anim."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1194\/jlr.M078220","article-title":"Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL","volume":"58","author":"Larsson","year":"2017","journal-title":"J. Lipid Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2020.00474","article-title":"The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans","volume":"11","author":"Packard","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"100068","DOI":"10.1016\/j.jlr.2021.100068","article-title":"ApoA5 lowers triglyceride levels via suppression of ANGPTL3\/8-mediated LPL inhibition","volume":"62","author":"Chen","year":"2021","journal-title":"J. Lipid Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20070308","article-title":"Apolipoprotein C-III: Understanding an emerging cardiovascular risk factor","volume":"114","author":"Ooi","year":"2008","journal-title":"Clin. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1016\/S0021-9258(19)39557-2","article-title":"Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV","volume":"265","author":"Goldberg","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"23610","DOI":"10.1016\/S0021-9258(17)31559-4","article-title":"Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia","volume":"269","author":"Maeda","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2337\/dc16-0126","article-title":"Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes","volume":"39","author":"Digenio","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11883-020-00836-w","article-title":"Efficacy and Safety of Volanesorsen (ISIS 304801): The Evidence from Phase 2 and 3 Clinical Trials","volume":"22","author":"Fogacci","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/cvr\/cvv192","article-title":"Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: The effect of authentic triglyceride-rich lipoproteins with and without ApoCIII","volume":"107","author":"Li","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1161\/CIRCGENETICS.113.000369","article-title":"Rare variant APOC3 R19X is associated with cardio-protective profiles in a diverse population-based survey as part of the Epidemiologic Architecture for Genes Linked to Environment Study","volume":"7","author":"Crawford","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Crawford, D.C., Restrepo, N.A., Diggins, K.E., Farber-Eger, E., and Wells, Q.S. (2018). Frequency and phenotype consequence of APOC3 rare variants in patients with very low triglyceride levels. BMC Med. Genom., 11.","DOI":"10.1186\/s12920-018-0387-1"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","article-title":"APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137\u2009895 Individuals","volume":"38","author":"Wulff","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/17512433.2022.2094768","article-title":"Safety and efficacy of therapies for chylomicronemia","volume":"15","author":"Shamsudeen","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase","volume":"27","author":"Shimamura","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng814","article-title":"Angptl3 regulates lipid metabolism in mice","volume":"30","author":"Koishi","year":"2002","journal-title":"Nat. Genet."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbalip.2011.10.010","article-title":"Regulation of triglyceride metabolism by Angiopoietin-like proteins","volume":"1821","author":"Mattijssen","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1074\/jbc.M808477200","article-title":"The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms","volume":"284","author":"Shan","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12020-015-0838-9","article-title":"The role of ANGPTL3 in controlling lipoprotein metabolism","volume":"52","author":"Tikka","year":"2016","journal-title":"Endocrine"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cca.2011.11.020","article-title":"Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation","volume":"413","author":"Roig","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11883-021-00972-x","article-title":"Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors","volume":"23","author":"Pirillo","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1073\/pnas.83.3.792","article-title":"Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17 alpha-ethinyl estradiol","volume":"83","author":"Ma","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0022-2275(20)38222-5","article-title":"Regulation of hepatic cholesterol and lipoprotein metabolism in ethinyl estradiol-treated rats","volume":"30","author":"Erickson","year":"1989","journal-title":"J. Lipid Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1432-1033.1993.tb18171.x","article-title":"In vivo regulation of low-density lipoprotein receptors by estrogen differs at the post-transcriptional level in rat and mouse","volume":"216","author":"Srivastava","year":"1993","journal-title":"Eur. J. Biochem."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0005-2760(91)90151-7","article-title":"In vivo regulation of low-density lipoprotein receptor and apolipoprotein B gene expressions by dietary fat and cholesterol in inbred strains of mice","volume":"1086","author":"Srivastava","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/ATVBAHA.111.237693","article-title":"Animal models of atherosclerosis","volume":"32","author":"Getz","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"126","DOI":"10.12998\/wjcc.v2.i5.126","article-title":"Animal models of atherosclerosis","volume":"2","author":"Kapourchali","year":"2014","journal-title":"World J. Clin. Cases"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1126\/science.3344433","article-title":"Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice","volume":"239","author":"Hofmann","year":"1988","journal-title":"Science"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11010-005-9053-y","article-title":"Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice","volume":"285","author":"Srivastava","year":"2006","journal-title":"Mol. Cell. Biochem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/CIRCULATIONAHA.106.684704","article-title":"Macrophage expression of peroxisome proliferator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"116","author":"Babaev","year":"2007","journal-title":"Circulation"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/ATVBAHA.113.301830","article-title":"Peroxisome proliferator-activated receptor delta agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice","volume":"34","author":"Bojic","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1074\/jbc.274.4.2366","article-title":"Decreased atherosclerosis in heterozygous low density lipoprotein receptor-deficient mice expressing the scavenger receptor BI transgene","volume":"274","author":"Arai","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1161\/ATVBAHA.108.175257","article-title":"Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice","volume":"28","author":"Teupser","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1411543","article-title":"Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E","volume":"258","author":"Zhang","year":"1992","journal-title":"Science"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0092-8674(92)90362-G","article-title":"Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells","volume":"71","author":"Plump","year":"1992","journal-title":"Cell"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.atherosclerosis.2011.11.024","article-title":"The effect of ABCG1 deficiency on atherosclerotic lesion development in LDL receptor knockout mice depends on the stage of atherogenesis","volume":"221","author":"Meurs","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/aps.2013.10","article-title":"Apolipoprotein A-I inhibits LPS-induced atherosclerosis in ApoE(\u2212\/\u2212) mice possibly via activated STAT3-mediated upregulation of tristetraprolin","volume":"34","author":"Yin","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1161\/01.ATV.0000240051.22944.dc","article-title":"Impaired development of atherosclerosis in hyperlipidemic Ldlr\u2212\/\u2212 and ApoE\u2212\/\u2212 mice transplanted with Abcg1\u2212\/\u2212 bone marrow","volume":"26","author":"Baldan","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e86442","DOI":"10.1172\/jci.insight.86442","article-title":"Atherogenesis and metabolic dysregulation in LDL receptor-knockout rats","volume":"2","author":"Sithu","year":"2017","journal-title":"JCI Insight"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"28795","DOI":"10.1074\/jbc.M204568200","article-title":"Ameliorated hepatic insulin resistance is associated with normalization of microsomal triglyceride transfer protein expression and reduction in very low density lipoprotein assembly and secretion in the fructose-fed hamster","volume":"277","author":"Carpentier","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11010-010-0573-8","article-title":"Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster","volume":"345","author":"Srivastava","year":"2010","journal-title":"Mol. Cell. Biochem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0021-9150(87)90106-7","article-title":"The hyperlipidemic hamster as a model of experimental atherosclerosis","volume":"68","author":"Nistor","year":"1987","journal-title":"Atherosclerosis"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2010.10.033","article-title":"Evaluation of anti-atherosclerotic activities of PPAR-alpha, PPAR-gamma, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters","volume":"214","author":"Srivastava","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0300-9629(91)90263-C","article-title":"The association of hepatic apoprotein and lipid metabolism in hamsters and rats","volume":"99","author":"Liu","year":"1991","journal-title":"Comp. Biochem. Physiol. A Comp. Physiol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0006-291X(92)92360-A","article-title":"Hormonal and nutritional stimuli modulate apolipoprotein B mRNA editing in mouse liver","volume":"188","author":"Srivastava","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1172\/JCI113321","article-title":"Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster","volume":"81","author":"Spady","year":"1988","journal-title":"J. Clin. Investig."},{"key":"ref_154","first-page":"3116","article-title":"An interspecies study of lipid profiles and atherosclerosis in familial hypercholesterolemia animal models with low-density lipoprotein receptor deficiency","volume":"11","author":"He","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ebiom.2017.12.013","article-title":"LDL Receptor Gene-ablated Hamsters: A Rodent Model of Familial Hypercholesterolemia with Dominant Inheritance and Diet-induced Coronary Atherosclerosis","volume":"27","author":"Guo","year":"2018","journal-title":"eBioMedicine"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Wang, J., He, K., Yang, C., Lin, X., Zhang, X., Wang, Y., Liu, G., and Xian, X. (2019). Dietary Cholesterol Is Highly Associated with Severity of Hyperlipidemia and Atherosclerotic Lesions in Heterozygous LDLR-Deficient Hamsters. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143515"},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Wu, Y., Xu, M.J., Cao, Z., Yang, C., Wang, J., Wang, B., Liu, J., Wang, Y., Xian, X., and Zhang, F. (2019). Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20235936"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"103831","DOI":"10.1016\/j.ejmg.2019.103831","article-title":"Familial hypercholesterolemia: A complex genetic disease with variable phenotypes","volume":"63","author":"Giacobbe","year":"2020","journal-title":"Eur. J. Med. Genet."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"871","DOI":"10.7326\/0003-4819-89-6-871","article-title":"Plasma high-density lipoproteins and ischemic heart disease: Studies in a large kindred with familial hypercholesterolemia","volume":"89","author":"Streja","year":"1978","journal-title":"Ann. Intern. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0022-2275(20)32184-2","article-title":"Correction of hypoalphalipoproteinemia in LDL receptor-deficient rabbits by lecithin:cholesterol acyltransferase","volume":"39","author":"Brousseau","year":"1998","journal-title":"J. Lipid Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0021-9150(80)90234-8","article-title":"Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL-rabbit)","volume":"36","author":"Watanabe","year":"1980","journal-title":"Atherosclerosis"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0014-5793(80)81223-3","article-title":"WHHL-rabbit: A low density lipoprotein receptor-deficient animal model for familial hypercholesterolemia","volume":"118","author":"Tanzawa","year":"1980","journal-title":"FEBS Lett."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1126\/science.3010466","article-title":"Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit","volume":"232","author":"Yamamoto","year":"1986","journal-title":"Science"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.CIR.79.5.1084","article-title":"Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine","volume":"79","author":"Kume","year":"1989","journal-title":"Circulation"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Davis, B.T., Wang, X.J., Rohret, J.A., Struzynski, J.T., Merricks, E.P., Bellinger, D.A., Rohret, F.A., Nichols, T.C., and Rogers, C.S. (2014). Targeted disruption of LDLR causes hypercholesterolemia and atherosclerosis in Yucatan miniature pigs. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0093457"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/0192623315622304","article-title":"A Translational Model for Diet-related Atherosclerosis: Effect of Statins on Hypercholesterolemia and Atherosclerosis in a Minipig","volume":"44","author":"Amuzie","year":"2016","journal-title":"Toxicol. Pathol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e002779","DOI":"10.1161\/JAHA.115.002779","article-title":"Development of Human-Like Advanced Coronary Plaques in Low-Density Lipoprotein Receptor Knockout Pigs and Justification for Statin Treatment Before Formation of Atherosclerotic Plaques","volume":"5","author":"Li","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1161\/ATVBAHA.117.310676","article-title":"Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient (LDLR(+\/\u2212) and LDLR(\u2212\/\u2212)) Yucatan Miniature Pigs","volume":"38","author":"Burke","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/labinvest.2017.47","article-title":"Accelerated atherosclerosis development in C57Bl6 mice by overexpressing AAV-mediated PCSK9 and partial carotid ligation","volume":"97","author":"Kumar","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Small, A.M., Huffman, J.E., Klarin, D., Lynch, J.A., Assimes, T., DuVall, S., Sun, Y.V., Shere, L., Natarajan, P., and Gaziano, M. (2020). PCSK9 loss of function is protective against extra-coronary atherosclerotic cardiovascular disease in a large multi-ethnic cohort. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0239752"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e21754","DOI":"10.1097\/MD.0000000000021754","article-title":"Loss-of-function mutation of PCSK9 as a protective factor in the clinical expression of familial hypercholesterolemia: A case report","volume":"99","author":"Bayona","year":"2020","journal-title":"Medicine"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.atherosclerosis.2019.08.020","article-title":"The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9","volume":"289","author":"Uribe","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/JEP.S267376","article-title":"Novel Experimental Agents for the Treatment of Hypercholesterolemia","volume":"13","author":"Reiner","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e220019","DOI":"10.1530\/EC-22-0019","article-title":"Effects of statins on the inducible degrader of low-density lipoprotein receptor in familial hypercholesterolemia","volume":"11","author":"Chan","year":"2022","journal-title":"Endocr. Connect."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/CIRCRESAHA.115.304008","article-title":"AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia","volume":"115","author":"Somanathan","year":"2014","journal-title":"Circ. Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.omtn.2021.10.008","article-title":"Drug discovery and development scheme for liver-targeting bridged nucleic acid antisense oligonucleotides","volume":"26","author":"Wada","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1126\/science.1168974","article-title":"LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor","volume":"325","author":"Zelcer","year":"2009","journal-title":"Science"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1889632","DOI":"10.1155\/2022\/1889632","article-title":"Idol Depletion Protects against Spontaneous Atherosclerosis in a Hamster Model of Familial Hypercholesterolemia","volume":"2022","author":"Liang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1161\/ATVBAHA.113.302670","article-title":"Hepatic overexpression of idol increases circulating protein convertase subtilisin\/kexin type 9 in mice and hamsters via dual mechanisms: Sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways","volume":"34","author":"Sasaki","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"100300","DOI":"10.1016\/j.jhepr.2021.100300","article-title":"Novel vectors and approaches for gene therapy in liver diseases","volume":"3","author":"Maestro","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1194\/jlr.M093740","article-title":"ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance","volume":"60","author":"Ramms","year":"2019","journal-title":"J. Lipid Res."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Nordestgaard","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/s41598-017-02601-7","article-title":"ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/ATVBAHA.116.307385","article-title":"Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus\u2014Brief Report","volume":"36","author":"Apro","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Chen, P.Y., Gao, W.Y., Liou, J.W., Lin, C.Y., Wu, M.J., and Yen, J.H. (2021). Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147310"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"100101","DOI":"10.1016\/j.jlr.2021.100101","article-title":"Antisense oligonucleotide-mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice","volume":"62","author":"Bell","year":"2021","journal-title":"J. Lipid Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3389\/fphys.2018.01222","article-title":"Lack of Correlation of Plasma HDL with Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis","volume":"9","author":"Srivastava","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11010-020-03826-3","article-title":"NPC1L1 and ABCG5\/8 induction explain synergistic fecal cholesterol excretion in ob\/ob mice co-treated with PPAR-\u03b1 and LXR agonists","volume":"473","author":"Srivastava","year":"2020","journal-title":"Mol. Cell. Biochem."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Gretarsdottir, S., Helgason, H., Helgadottir, A., Sigurdsson, A., Thorleifsson, G., Magnusdottir, A., Oddsson, A., Steinthorsdottir, V., Rafnar, T., and de Graaf, J. (2015). A Splice Region Variant in LDLR Lowers Non-high Density Lipoprotein Cholesterol and Protects against Coronary Artery Disease. PLoS Genet., 11.","DOI":"10.1371\/journal.pgen.1005379"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e003029","DOI":"10.1161\/CIRCGEN.120.003029","article-title":"Lifelong Reduction in LDL (Low-Density Lipoprotein) Cholesterol due to a Gain-of-Function Mutation in LDLR","volume":"14","author":"Bjornsson","year":"2021","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in Patients with Refractory Hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_197","first-page":"1023","article-title":"Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia","volume":"6","author":"Kostner","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"ref_199","first-page":"601","article-title":"Role of orthotopic liver transplant in the treatment of homozygous familial hypercholesterolemia","volume":"92","author":"Fraga","year":"2000","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J. Clin. Lipidol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1053\/jhep.2003.50183","article-title":"Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors","volume":"37","author":"Oertel","year":"2003","journal-title":"Hepatology"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1038\/s41598-019-43459-1","article-title":"Bile-duct proliferation as an unexpected side-effect after AAV2-LDLR gene transfer to rabbit liver","volume":"9","author":"Laurema","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41434-019-0061-z","article-title":"Helper-dependent adenovirus-mediated gene transfer of a secreted LDL receptor\/transferrin chimeric protein reduces aortic atherosclerosis in LDL receptor-deficient mice","volume":"26","author":"Leggiero","year":"2019","journal-title":"Gene Ther."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Kassim, S.H., Li, H., Vandenberghe, L.H., Hinderer, C., Bell, P., Marchadier, D., Wilson, A., Cromley, D., Redon, V., and Yu, H. (2010). Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013424"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.7150\/thno.49874","article-title":"Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/hum.2012.108","article-title":"Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia","volume":"24","author":"Kassim","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2021.04.017","article-title":"Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia","volume":"22","author":"Wang","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/gt.2016.37","article-title":"Construction of minicircle DNA vectors capable of correcting familial hypercholesterolemia phenotype in a LDLR-deficient mouse model","volume":"23","author":"Hou","year":"2016","journal-title":"Gene Ther."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In Vivo AAV-CRISPR\/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation"},{"key":"ref_211","first-page":"466","article-title":"CRISPR-based Gene Editing Enhances LDLR Expression and Boosts LDL-C Uptake in Familial Hypercholesterolemia","volume":"30","author":"Lev","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"e2020401118","DOI":"10.1073\/pnas.2020401118","article-title":"Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3","volume":"118","author":"Qiu","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1161\/ATVBAHA.117.309881","article-title":"In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin\/Kexin Type 9) as a Therapeutic Alternative to Genome Editing","volume":"37","author":"Chadwick","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1093\/eurheartj\/ehac544.3087","article-title":"An in vivo CRISPR base editing therapy to inactivate ANGPTL3: Nomination of a development candidate for VERVE-201","volume":"43","author":"Khera","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep4.1110","article-title":"CRISPR Correction of a Homozygous Low-Density Lipoprotein Receptor Mutation in Familial Hypercholesterolemia Induced Pluripotent Stem Cells","volume":"1","author":"Omer","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13059-018-1515-0","article-title":"All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo","volume":"19","author":"Ibraheim","year":"2018","journal-title":"Genome Biol."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1038\/s41598-019-41056-w","article-title":"Function and Immunogenicity of Gene-corrected iPSC-derived Hepatocyte-Like Cells in Restoring Low Density Lipoprotein Uptake in Homozygous Familial Hypercholesterolemia","volume":"9","author":"Okada","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jimd.12251","article-title":"Opportunities and challenges for antisense oligonucleotide therapies","volume":"44","author":"Kuijper","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s13258-020-01002-x","article-title":"CRISPR: A journey of gene-editing based medicine","volume":"42","author":"Golkar","year":"2020","journal-title":"Genes Genom."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.addr.2020.06.026","article-title":"Lipid nanoparticle technology for therapeutic gene regulation in the liver","volume":"159","author":"Witzigmann","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/sj.gt.3302364","article-title":"Immune responses to gene therapy vectors: Influence on vector function and effector mechanisms","volume":"11","author":"Bessis","year":"2004","journal-title":"Gene Ther."},{"key":"ref_225","first-page":"1","article-title":"Lipid nanoparticles incorporating a GalNAc ligand enable in vivo liver ANGPTL3 editing in wild-type and somatic LDLR knockout non-human primates","volume":"10","author":"Kasiewicz","year":"2021","journal-title":"bioRxiv"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41576-018-0068-0","article-title":"Publisher Correction: Base editing: Precision chemistry on the genome and transcriptome of living cells","volume":"19","author":"Rees","year":"2018","journal-title":"Nat. Rev. Genet."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Kantor, A., McClements, M.E., and MacLaren, R.E. (2020). CRISPR-Cas9 DNA Base-Editing and Prime-Editing. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176240"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"14500","DOI":"10.1038\/ncomms14500","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.116.307227","article-title":"CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo\u2014Brief Report","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Carreras, A., Pane, L.S., Nitsch, R., Madeyski-Bengtson, K., Porritt, M., Akcakaya, P., Taheri-Ghahfarokhi, A., Ericson, E., Bjursell, M., and Perez-Alcazar, M. (2019). In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model. BMC Biol., 17.","DOI":"10.1186\/s12915-018-0624-2"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/12\/1648\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:56:38Z","timestamp":1760126198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/12\/1648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":230,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["cells12121648"],"URL":"https:\/\/doi.org\/10.3390\/cells12121648","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]}}}